stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
29.94
0.20
−0.66%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Total debt
Vera Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $74.8M, up 47.6% from $50.7M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $75.2M. Over the past ten years it has ranged from $2.0K (fiscal 2020) to $74.8M (fiscal 2025) — the current reading is the highest in ten years. Vera Therapeutics, Inc. ranks 108th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $74.8M | 47.65% |
| FY2024 | $50.7M | 1.62% |
| FY2023 | $49.9M | 101.04% |
| FY2022 | $24.8M | 403.96% |
| FY2021 | $4.9M | 246,050.00% |
| FY2020 | $2.0K | (80.00%) |
| FY2019 | $10.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $75.2M | 0.27% |
| Mar 2026 | $75.0M | 0.26% |
| Dec 2025 | $74.8M | 0.25% |
| Sep 2025 | $74.6M | 0.25% |
| 16 more quarters | Free account |
Against its own ten years
Low $2.0K
High $74.8M
Ten-year median
$24.8M
Current reading's percentile
100
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $5.5M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt